JP2004507440A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004507440A5 JP2004507440A5 JP2001519909A JP2001519909A JP2004507440A5 JP 2004507440 A5 JP2004507440 A5 JP 2004507440A5 JP 2001519909 A JP2001519909 A JP 2001519909A JP 2001519909 A JP2001519909 A JP 2001519909A JP 2004507440 A5 JP2004507440 A5 JP 2004507440A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- resistant
- penicillin
- pathogen
- sensitive
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 description 10
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 6
- 241000894006 Bacteria Species 0.000 description 4
- 229930182555 Penicillin Natural products 0.000 description 4
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 4
- 244000052769 pathogen Species 0.000 description 4
- 229940049954 penicillin Drugs 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 3
- 229960003405 ciprofloxacin Drugs 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 241000193998 Streptococcus pneumoniae Species 0.000 description 2
- 229960003170 gemifloxacin Drugs 0.000 description 2
- -1 gemifloxacin compound Chemical class 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 229940031000 streptococcus pneumoniae Drugs 0.000 description 2
- 206010035664 Pneumonia Diseases 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000018406 regulation of metabolic process Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
Applications Claiming Priority (36)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15183499P | 1999-09-01 | 1999-09-01 | |
| US15183799P | 1999-09-01 | 1999-09-01 | |
| US15196099P | 1999-09-01 | 1999-09-01 | |
| US15183599P | 1999-09-01 | 1999-09-01 | |
| US15191799P | 1999-09-01 | 1999-09-01 | |
| US15183699P | 1999-09-01 | 1999-09-01 | |
| US15411599P | 1999-09-14 | 1999-09-14 | |
| US15388499P | 1999-09-14 | 1999-09-14 | |
| US15538399P | 1999-09-22 | 1999-09-22 | |
| US15538199P | 1999-09-22 | 1999-09-22 | |
| US15535999P | 1999-09-22 | 1999-09-22 | |
| US15534899P | 1999-09-22 | 1999-09-22 | |
| US15514899P | 1999-09-22 | 1999-09-22 | |
| US15533899P | 1999-09-22 | 1999-09-22 | |
| US15534699P | 1999-09-22 | 1999-09-22 | |
| US15534099P | 1999-09-22 | 1999-09-22 | |
| US15538299P | 1999-09-22 | 1999-09-22 | |
| US15534999P | 1999-09-22 | 1999-09-22 | |
| US15537999P | 1999-09-22 | 1999-09-22 | |
| US15539199P | 1999-09-22 | 1999-09-22 | |
| US15515099P | 1999-09-22 | 1999-09-22 | |
| US15539399P | 1999-09-22 | 1999-09-22 | |
| US15534499P | 1999-09-22 | 1999-09-22 | |
| US15539299P | 1999-09-22 | 1999-09-22 | |
| US15534799P | 1999-09-22 | 1999-09-22 | |
| US15539499P | 1999-09-22 | 1999-09-22 | |
| US15538499P | 1999-09-22 | 1999-09-22 | |
| US15536099P | 1999-09-22 | 1999-09-22 | |
| US15539599P | 1999-09-22 | 1999-09-22 | |
| US15514999P | 1999-09-22 | 1999-09-22 | |
| US15535899P | 1999-09-22 | 1999-09-22 | |
| US15538099P | 1999-09-22 | 1999-09-22 | |
| US15586899P | 1999-09-24 | 1999-09-24 | |
| US15595799P | 1999-09-24 | 1999-09-24 | |
| US15586999P | 1999-09-24 | 1999-09-24 | |
| PCT/US2000/023883 WO2001015695A1 (en) | 1999-09-01 | 2000-08-31 | Methods of use of fluoroquinolone compounds against bacteria |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2004507440A JP2004507440A (ja) | 2004-03-11 |
| JP2004507440A5 true JP2004507440A5 (enrdf_load_stackoverflow) | 2007-10-18 |
Family
ID=27586941
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001519909A Pending JP2004507440A (ja) | 1999-09-01 | 2000-08-31 | 細菌に対するフルオロキノロン化合物の使用法 |
Country Status (4)
| Country | Link |
|---|---|
| EP (1) | EP1401440A4 (enrdf_load_stackoverflow) |
| JP (1) | JP2004507440A (enrdf_load_stackoverflow) |
| AU (1) | AU6947900A (enrdf_load_stackoverflow) |
| WO (1) | WO2001015695A1 (enrdf_load_stackoverflow) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9920919D0 (en) | 1999-09-03 | 1999-11-10 | Sb Pharmco Inc | Novel compound |
| GB9920917D0 (en) | 1999-09-03 | 1999-11-10 | Sb Pharmco Inc | Novel process |
| ATE410225T1 (de) | 2001-08-02 | 2008-10-15 | Lg Life Sciences Ltd | Verfahren zur herstellung von amino-geschützten 4-aminomethylene-pyrrolidin-3-on-derivaten, gemifloxacin und deren salze |
| KR100517638B1 (ko) | 2002-04-08 | 2005-09-28 | 주식회사 엘지생명과학 | 게미플록사신 산염의 새로운 제조방법 |
-
2000
- 2000-08-31 JP JP2001519909A patent/JP2004507440A/ja active Pending
- 2000-08-31 EP EP00993844A patent/EP1401440A4/en not_active Withdrawn
- 2000-08-31 WO PCT/US2000/023883 patent/WO2001015695A1/en active Application Filing
- 2000-08-31 AU AU69479/00A patent/AU6947900A/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Gendron et al. | The oral cavity as a reservoir of bacterial pathogens for focal infections | |
| WO2000010582A3 (en) | Probiotic, lactic acid-producing bacteria and uses thereof | |
| EP1194525B1 (en) | Combination of lactic acid bacteria and its use for the prevention and/or treatment of infections and inflammatory conditions | |
| CA2414576A1 (en) | Promoting whole body health | |
| RU2011129693A (ru) | Композиции и способы улучшения здоровья полости рта | |
| Herzon | Bacteremia and local infections with nasal packing | |
| JP2002522464A5 (enrdf_load_stackoverflow) | ||
| Kenna et al. | Microbiology of chronic suppurative otitis media in children | |
| Pajukanta et al. | In vitro antimicrobial susceptibility of different serotypes of Actinobacillus actinomycetemcomitans | |
| SCHAFER et al. | Infectious endocarditis caused by Rothia dentocariosa | |
| Brook | Pathogenicity of the Bacteroides fragilis group | |
| JP2003533489A5 (enrdf_load_stackoverflow) | ||
| JP2004507440A5 (enrdf_load_stackoverflow) | ||
| Fernandez et al. | Failure of rifampin to eradicate group B streptococcal colonization in infants | |
| Ahmed et al. | Biofilm formation and autoinducer‐2 signaling in Streptococcus intermedius: role of thermal and pH factors | |
| CA2200054A1 (en) | Use of antibodies to block the effects of gram-positive bacteria and mycobacteria | |
| Freeman | Short-term adverse effects of antibiotic prophylaxis for open-heart surgery. | |
| DE69419782D1 (de) | Multimeres alpha-lactalbumin enthaltende antibakterielle zusammensetzung | |
| Guze et al. | The role of antibiotic tolerance in the response to treatment of pyelonephritis due to Staphylococcus aureus in rats | |
| Caufield et al. | In vitro susceptibility of Streptococcus mutans 6715 to iodine and sodium fluoride, singly and in combination, at various pH values | |
| Bystedt et al. | Ecological effects of penicillin prophylaxis in orthognatic surgery | |
| Unnikrishnan et al. | Complementation of a speA negative Streptococcus pyogenes with speA: effects on virulence and production of streptococcal pyrogenic exotoxin A | |
| Ginsburg | Streptococcus. | |
| Odenholt et al. | Studies of the killing kinetics of benzylpenicillin, cefuroxime, azithromycin, and sparfloxacin on bacteria in the postantibiotic phase | |
| Arguedas et al. | In vitro activity of tosufloxacin, a new quinolone, against respiratory pathogens derived from cystic fibrosis sputum |